StreetInsider.com News Articles

ImmunityBio reports 3-year bladder preservation data for Anktiva plus BCG

Fri, 16 Oct 2026 11:49:16 -0400

ImmunityBio, Inc. (NASDAQ: IBRX) announced the publication of long-term data from its Phase 2/3 QUILT-3.032 study in the Journal of Urology, showing three-year outcomes for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary disease, treated with ANKTIVA (nogapendekin alfa inbakicept-pmln) combined with BCG.

The study, which enrolled 100 patients, reported a 71% complete response (CR) rate. The median duration of CR was 26.6 months, with some responses extending beyond 53 months. Among responders, 84% remained cystectomy-free at 36 months, and 98.2% achieved disease-specific survival at three years. Progression-free survival stood at 80.9%

ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Pap

Fri, 16 Oct 2026 11:49:00 -0400

Peer-reviewed publication reports long-term outcomes from the QUILT-3.032 study supporting durable disease control and bladder preservation

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the publication of long-term data from the Phase 2/3 QUILT-3.032 study (N=100) in the Journal of Urology. The study evaluated ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary disease.

Highlights:

71% complete response (CR) rate in patients with BCG-unresponsive NMIBC CIS, with or without

ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Pap

Fri, 16 Oct 2026 11:49:00 -0400

Peer-reviewed publication reports long-term outcomes from the QUILT-3.032 study supporting durable disease control and bladder preservation

Highlights:

71% complete response (CR) rate in patients with BCG-unresponsive NMIBC CIS, with or without

H.C. Wainwright Reiterates Buy Rating on Immunitybio Inc (IBRX)

Thu, 15 Oct 2026 06:57:39 -0400

H.C. Wainwright analyst Andres Maldonado reiterated a Buy rating and $15.00 price target on Immunitybio Inc (NASDAQ: IBRX).

The analyst commented: "Yesterday, the FDA expanded ANKTIVA approval to include high-risk BCG-unresponsive NMIBC papillary-only disease, building upon an original approval in CIS +/- papillary disease. This marks the first FDA approval to include papillary-only disease, which represents upwards of 60% of all high-risk BCG-UR NMIBC patients, a population whose value was always reflected in our models. The label extension was based on the previously demonstrated efficacy of ANKTIVA plus BCG in patients with CIS +/- papillary where 62% of patients (95% CI:

Form 8-K ImmunityBio, Inc. For: Oct 14

Wed, 14 Oct 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20261014/27187925.html

Immunitybio Inc (IBRX) PT Raised to $14 at Jefferies

Wed, 14 Oct 2026 16:34:46 -0400

Jefferies analyst Kelly Shi raised the price target on Immunitybio Inc (NASDAQ: IBRX) to $14.00 (from $12.00) while maintaining a Buy rating.

FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease

Wed, 14 Oct 2026 16:18:00 -0400

Expanded indication extends ANKTIVA plus BCG to patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC), including those with carcinoma in situ (CIS), with or without papillary tumors, and those with papillary-only tumors
Papillary disease represents approximately 85% of the NMIBC patient population1
This is the first FDA approval to include BCG-unresponsive NMIBC with papillary-only tumors
With this FDA approval, access to ANKTIVA plus BCG expands to include all patients with BCG-unresponsive NMIBC

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has expanded the approved indication for ANKTIVA®

FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease

Wed, 14 Oct 2026 16:18:00 -0400

Expanded indication extends ANKTIVA plus BCG to patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC), including those with carcinoma in situ (CIS), with or without papillary tumors, and those with papillary-only tumors
Papillary disease represents approximately 85% of the NMIBC patient population1
This is the first FDA approval to include BCG-unresponsive NMIBC with papillary-only tumors
With this FDA approval, access to ANKTIVA plus BCG expands to include all patients with BCG-unresponsive NMIBC

FDA expands Anktiva approval to include papillary-only bladder cancer

Wed, 14 Oct 2026 11:20:08 -0400

The Food and Drug Administration approved an expanded indication for nogapendekin alfa inbakicept-pmln (Anktiva, Altor BioScience, LLC, a subsidiary of ImmunityBio, Inc.) on October 14, 2026, broadening its use in adults with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).

The updated indication extends the drug's approved use beyond patients with carcinoma in situ (CIS) with or without papillary tumors to now include patients with high-grade papillary-only tumors. Anktiva is administered with Bacillus Calmette-Guérin (BCG).

The expanded approval was based on a review of available scientific information rather than a new clinical trial. The FDA determined that prior efficacy data from patients with BCG-unresponsive

FDA expands Anktiva approval to include papillary-only bladder cancer

Wed, 14 Oct 2026 11:20:08 -0400

The expanded approval was based on a review of available scientific information rather than a new clinical trial. The FDA determined that prior efficacy data from patients with BCG-unresponsive

FDA expands Anktiva approval to include papillary-only bladder cancer

Wed, 14 Oct 2026 11:20:08 -0400

The expanded approval was based on a review of available scientific information rather than a new clinical trial. The FDA determined that prior efficacy data from patients with BCG-unresponsive

ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium

Thu, 08 Oct 2026 08:30:00 -0400

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that Dr. Patrick Soon-Shiong, its Founder, Executive Chairman and Global Chief Scientific and Medical Officer, will participate virtually in a fireside chat at the Piper Sandler Virtual Oncology Symposium, taking place October 15-16, 2026.

Details of the event are provided below:

Piper Sandler Virtual Oncology Symposium – Fireside Chat
Participant: Patrick Soon-Shiong, M.D., Founder, Executive Chairman and Global Chief Scientific and Medical Officer, ImmunityBio
Moderator: Ted Tenthoff, Managing Director and Senior Research Analyst, Piper Sandler
Date: Friday, October 16, 2026
Time:

ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium

Thu, 08 Oct 2026 08:30:00 -0400

Details of the event are provided below:

Form 4 ImmunityBio, Inc. For: Oct 05 Filed by: Simon Barry J.

Tue, 06 Oct 2026 18:06:00 -0400

si-local-file:///var/storage/secattach/20261006/27156515.html

Form 4 ImmunityBio, Inc. For: Oct 02 Filed by: Cohen Cheryl

Tue, 06 Oct 2026 18:06:00 -0400

si-local-file:///var/storage/secattach/20261006/27156511.html

Form 144 ImmunityBio, Inc. Filed by: Simon Barry J.

Mon, 05 Oct 2026 10:22:00 -0400

si-local-file:///var/storage/secattach/20261005/27147117.html

Form 144 ImmunityBio, Inc. Filed by: Cohen Cheryl

Fri, 02 Oct 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20261002/27142698.html

These High-Voltage Stocks Are Suddenly Impossible to Ignore

Fri, 02 Oct 2026 11:44:09 -0400

DENVER, Oct. 02, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com)— Today’s market is driven by an outstanding mix of listings, including Alpha Modus Holdings (NASDAQ:AMOD), Stablecoin Development (NYSEAMERICAN:SDEV), ImmunityBio (NASDAQ:IBRX), and NeOnc Technologies Holdings (NASDAQ:NTHI).